WallStSmart
ANTX

AN2 Therapeutics Inc

NASDAQ: ANTX · HEALTHCARE · BIOTECHNOLOGY

$4.47
-1.76% today

Updated 2026-11-16

Market cap
$168.85M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.91
Dividend yield
—
52W range
$1 – $7
Volume
0.3M

WallStSmart proprietary scores

27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.8
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-2.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →252 stocks currently score above 75

Price targets

Analyst target
$9.00
+101.34%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -2.90 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.10M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-41.47M$-64.73M$-51.32M$-35.17M$-7.96M
EPS————$-0.91
Free cash flow$-33.46M$-53.29M$-49.26M$-29.83M$-6.10M
Profit margin—————

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
ANTX$168.85M274.33.05.04.8—Avoid
LLY$1.27T749.310.05.06.0—Strong Buy
JNJ$682.52B544.78.53.75.5—Buy
ABBV$520.47B776.79.04.05.0-87.62%Strong Buy
UNH$363.01B626.76.04.75.5-24.67%Buy
MRK$362.27B423.36.52.05.0-73.98%Hold

Smart narrative

AN2 Therapeutics Inc trades at $4.47. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -2.90, it sits in the distress.

Frequently asked questions

What is AN2 Therapeutics Inc's stock price?

AN2 Therapeutics Inc (ANTX) trades at $4.47.

Is AN2 Therapeutics Inc overvalued?

AN2 Therapeutics Inc carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of AN2 Therapeutics Inc (ANTX)?

The 12-month analyst consensus target is $9.00, about 101.3% above the current $4.47. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

AN2 Therapeutics Inc's Altman Z-Score is -2.90, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio—
ROE-42.26%
Beta-0.94
50D MA$4.64
200D MA$4.21
Shares out0.04B
Float0.02B
Short ratio—
Avg volume0.3M

Performance

1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—